[
  {
    "ts": null,
    "headline": "Here's Why Abbott (ABT) Fell More Than Broader Market",
    "summary": "In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=61cf21407a4297477cd0f66c58f5183c2b8943ea0133e4b69e41d7e8abcbac31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765234201,
      "headline": "Here's Why Abbott (ABT) Fell More Than Broader Market",
      "id": 137737856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=61cf21407a4297477cd0f66c58f5183c2b8943ea0133e4b69e41d7e8abcbac31"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
    "summary": "Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
    "url": "https://finnhub.io/api/news?id=92ace4c19bb14eb02948a808e2e8a12eeed025d2de91b01049574248f6471c2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765203681,
      "headline": "Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
      "id": 137732197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump",
      "url": "https://finnhub.io/api/news?id=92ace4c19bb14eb02948a808e2e8a12eeed025d2de91b01049574248f6471c2e"
    }
  },
  {
    "ts": null,
    "headline": "HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?",
    "summary": "Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.",
    "url": "https://finnhub.io/api/news?id=17df342f48228f81e26cef3e83fdaf998acc93eb5aae399416c84b2fc6bd1430",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765203540,
      "headline": "HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?",
      "id": 137732379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.",
      "url": "https://finnhub.io/api/news?id=17df342f48228f81e26cef3e83fdaf998acc93eb5aae399416c84b2fc6bd1430"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data",
    "summary": "Abbott (NYSE: ABT) today announced that Lingo, an over-the-counter continuous glucose monitor (CGM) and app, is now available for Android devices. Already available for Apple iOS devices, this expansion gives millions more people access to real-time glucose data, empowering informed choices that help support better energy, sleep, focus and overall well-being.i ii iii",
    "url": "https://finnhub.io/api/news?id=2b2a8503d7e662225e2d3d9f07816181d100e2b0c6fe7be0150247a780b59079",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765202400,
      "headline": "Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data",
      "id": 137732380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced that Lingo, an over-the-counter continuous glucose monitor (CGM) and app, is now available for Android devices. Already available for Apple iOS devices, this expansion gives millions more people access to real-time glucose data, empowering informed choices that help support better energy, sleep, focus and overall well-being.i ii iii",
      "url": "https://finnhub.io/api/news?id=2b2a8503d7e662225e2d3d9f07816181d100e2b0c6fe7be0150247a780b59079"
    }
  },
  {
    "ts": null,
    "headline": "2 Mega-Cap Stocks with Promising Prospects and 1 Facing Challenges",
    "summary": "\"Too big to fail\" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.",
    "url": "https://finnhub.io/api/news?id=c7084f0629955811e2bd2c5b3ae7005d2f4ea708dbc00f978a1b36d6cc8e4d09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765168895,
      "headline": "2 Mega-Cap Stocks with Promising Prospects and 1 Facing Challenges",
      "id": 137732224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "\"Too big to fail\" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.",
      "url": "https://finnhub.io/api/news?id=c7084f0629955811e2bd2c5b3ae7005d2f4ea708dbc00f978a1b36d6cc8e4d09"
    }
  }
]